6084 Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study)

M.Ducreux; A.Adenis; J.P.Pignon; E.Fran?ois; B.Chauffert; E.Boucher; M.Ychou; J.Y.Pierga; C.Montot-Grillot; T.Conroy

首页> 外文期刊>European Journal of Cancer Supplements >6084 Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study)

【24h】

6084 Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study)

机译：6084基于贝伐单抗的联合方案对转移性结直肠癌患者的疗效和安全性：贝伐单抗+ FOLFIRI与贝伐单抗+ XELIRI的随机II期研究的最终结果（FNCLCC ACCORD 13/0503研究）

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共2页
作者
M.Ducreux; A.Adenis; J.P.Pignon; E.Fran?ois; B.Chauffert; E.Boucher; M.Ychou; J.Y.Pierga; C.Montot-Grillot; T.Conroy;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 6084 Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study) [J] . M.Ducreux, A.Adenis, J.P.Pignon, European Journal of Cancer Supplements . 2009,第2期

机译：6084基于贝伐单抗的联合方案对转移性结直肠癌患者的疗效和安全性：贝伐单抗+ FOLFIRI与贝伐单抗+ XELIRI的随机II期研究的最终结果（FNCLCC ACCORD 13/0503研究）
2. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study) [J] . DucreuxM., AdenisA., PignonJ.-P., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2013,第6期

机译：以贝伐单抗为基础的联合方案对先前未治疗的转移性结直肠癌患者的疗效和安全性：贝伐单抗+ 5-氟尿嘧啶，亚叶酸钙+伊立替康与贝伐单抗+卡培他滨+伊立替康的ii期随机研究的最终结果（FNCLCC ACCORD 13/0503研究）
3. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab [J] . Masahito Kotaka, Ruihua Xu, Kei Muro, Chinese journal of cancer . 2016,第1期

机译：亚洲XELIRI项目（AXEPT）的研究方案：一项针对转移性结直肠癌的二线化疗的跨国，非劣效，非劣效性III期临床试验，比较了有或没有贝伐单抗与有或没有贝伐单抗的FOLFIRI的疗效和安全性
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational randomized non-inferiority phase III trial of second-line chemotherapy for metastatic colorectal cancer comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab [O] . Masahito Kotaka, Ruihua Xu, Kei Muro, 2016

机译：亚洲XELIRI ProjecT（AXEPT）的研究方案：一项针对转移性结直肠癌的二线化疗的跨国非劣效非劣效性三期临床试验比较了XELIRI联合或不联合贝伐单抗与FOLFIRI联合或不联合贝伐单抗的疗效和安全性
7. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab [O] . 2016

机译：亚洲XELIRI ProjecT（AXEPT）的研究方案：一项针对转移性结直肠癌的二线化疗的跨国，非劣效，非劣效性三期临床试验，比较了XELIRI联合或不联合贝伐单抗与FOLFIRI联合或不联合贝伐单抗的疗效和安全性

6084 Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study)

著录项

相似文献

相关主题

期刊订阅